Philip W. Labuschagne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Philip W. Labuschagne has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Emmanuel Rotimi Sadiku
Department of Chemical, Metallurgical and Materials Engineering, Tshwane University of Technology, Pretoria, 0001, South Africa
4 shared publications - Francis Sean Moolman
Materials Science and Manufacturing, CSIR, Pretoria, South Africa
4 shared publications Lonji Kalombo
Centre for Polymers and Composites, Council for Scientific and Industrial Research, Pretoria, South Africa
4 shared publications- Hulda Swai
Department of Global Health and Biomedical Sciences, School of Life Sciences and Bioengineering, The Nelson Mandela African Institution of Science and Technology
3 shared publications Mohammed Balogun
Centre for Nanostructures and Advanced Materials, Council for Scientific and Industrial Research, South Africa
3 shared publications- Abdullahi Ahmed Yusuf
Department of Zoology and Entomology, University of Pretoria, Hatfield, South Africa
2 shared publications
Latest Publications
- 1 May 2020
- Published by Elsevier in Journal of CO2 Utilization
- Vol. 38, 375-384
CO2-assisted production of polyethylene glycol / lauric acid microparticles for extended release of Citrus aurantifolia essential oil
- 1 May 2020
- Published by Elsevier in Journal of CO2 Utilization
- Vol. 38, 375-384
CO2-assisted production of polyethylene glycol / lauric acid microparticles for extended release of Citrus aurantifolia essential oil
- Open Access
- 23 October 2019
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 9 (58) , 34039-34049
Microencapsulation of eucalyptol in polyethylene glycol and polycaprolactone using particles from gas-saturated solutions
Eucalyptol is the natural cyclic ether which constitutes the bulk of terpenoids found in essential oils of Eucalyptus spp. and is used in aromatherapy for treatment of migraine, sinusitis, asthma and stress. It acts by inhibiting arachidonic acid metabolism and cytokine production. Chemical instability and volatility of eucalyptol restrict its therapeutic application and necessitate the need to develop an appropriate delivery system to achieve extended release and enhance its bioactivity. However, the synthesis method of the delivery system must be suitable to prevent loss or inactivation of the drug during processing. In this study, supercritical carbon dioxide (scCO2) was explored as an alternative solvent for encapsulation and co-precipitation of eucalyptol with polyethylene glycol (PEG) and/or polycaprolactone (PCL) using the particles from gas-saturated solution (PGSS) process. Polymers and eucalyptol were pre-mixed and then processed in a PGSS autoclave at 45 °C and 80 bar for 1 h. The mixture in scCO2 was micronized and characterized. The presence of eucalyptol in the precipitated particles was confirmed by infrared spectroscopy, gas chromatography and mass spectrometry. The weight ratios of PEG–PCL blends significantly influenced loading capacity and encapsulation efficiency with 77% of eucalyptol encapsulated in a 4 : 1 composite blend of PEG–PCL. The particle size distribution of the PGSS-micronized particles ranged from 30 to 260 μm. ScCO2 assisted microencapsulation in PEG and PCL reduced loss of the volatile drug during a two-hour vaporization study and addition of PCL extended the mean release time in simulated physiological fluids. Free radical scavenging and lipoxygenase inhibitory activities of eucalyptol formulated in the PGSS-micronized particles was sustained. Findings from this study showed that the scCO2-assisted micronization can be used for encapsulation of volatile drugs in polymeric microparticles without affecting bioactivity of the drug.
- 23 October 2019
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 9 (58) , 34039-34049
Open AccessMicroencapsulation of eucalyptol in polyethylene glycol and polycaprolactone using particles from gas-saturated solutions
Eucalyptol is the natural cyclic ether which constitutes the bulk of terpenoids found in essential oils of Eucalyptus spp. and is used in aromatherapy for treatment of migraine, sinusitis, asthma and stress. It acts by inhibiting arachidonic acid metabolism and cytokine production. Chemical instability and volatility of eucalyptol restrict its therapeutic application and necessitate the need to develop an appropriate delivery system to achieve extended release and enhance its bioactivity. However, the synthesis method of the delivery system must be suitable to prevent loss or inactivation of the drug during processing. In this study, supercritical carbon dioxide (scCO2) was explored as an alternative solvent for encapsulation and co-precipitation of eucalyptol with polyethylene glycol (PEG) and/or polycaprolactone (PCL) using the particles from gas-saturated solution (PGSS) process. Polymers and eucalyptol were pre-mixed and then processed in a PGSS autoclave at 45 °C and 80 bar for 1 h. The mixture in scCO2 was micronized and characterized. The presence of eucalyptol in the precipitated particles was confirmed by infrared spectroscopy, gas chromatography and mass spectrometry. The weight ratios of PEG–PCL blends significantly influenced loading capacity and encapsulation efficiency with 77% of eucalyptol encapsulated in a 4 : 1 composite blend of PEG–PCL. The particle size distribution of the PGSS-micronized particles ranged from 30 to 260 μm. ScCO2 assisted microencapsulation in PEG and PCL reduced loss of the volatile drug during a two-hour vaporization study and addition of PCL extended the mean release time in simulated physiological fluids. Free radical scavenging and lipoxygenase inhibitory activities of eucalyptol formulated in the PGSS-micronized particles was sustained. Findings from this study showed that the scCO2-assisted micronization can be used for encapsulation of volatile drugs in polymeric microparticles without affecting bioactivity of the drug.
- 4 May 2019
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 62 (7) , 332-345
Preclinical assessment of 68Ga‐PSMA‐617 entrapped in a microemulsion delivery system for applications in prostate cancer PET/CT imaging
It has in recent years been reported that microemulsion (ME) delivery systems provide an opportunity to improve the efficacy of a therapeutic agent whilst minimising side effects and also offer the advantage of favourable treatment regimens. The prostate‐specific membrane antigen (PSMA) targeting agents PSMA‐11 and PSMA‐617, which accumulate in prostate tumours, allows for [68Ga]Ga3+‐radiolabelling and PET imaging of PSMA‐expression in vivo. We herein report the formulation of [68Ga]Ga‐PSMA‐617 into a ME ≤40 nm including its evaluation for improved cellular toxicity and in vivo biodistribution. The [68Ga]Ga‐PSMA‐617‐ME was tested in vitro for its cytotoxicity to HEK293 and PC3 cells. [68Ga]Ga‐PSMA‐617‐ME was administered intravenously in BALB/c mice followed by microPET/CT imaging and ex vivo biodistribution determination. [68Ga]Ga‐PSMA‐617‐ME indicated negligible cellular toxicity at different concentrations. A statistically higher tolerance towards the [68Ga]Ga‐PSMA‐617‐ME occurred at 0.125mg/ml by HEK293 cells compared to PC3 cells. The biodistribution in wild‐type BALB/C mice showed the highest amounts of radioactivity (%ID/g) presented in the kidneys (31%) followed by the small intestine (10%) and stomach (9%); the lowest uptake was seen in the brain (0.5%). The incorporation of [68Ga]Ga‐PSMA‐617 into ME was successfully demonstrated and resulted in a stable non‐toxic formulation as evaluated by in vitro and in vivo means.
- 4 May 2019
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 62 (7) , 332-345
Preclinical assessment of 68Ga‐PSMA‐617 entrapped in a microemulsion delivery system for applications in prostate cancer PET/CT imaging
It has in recent years been reported that microemulsion (ME) delivery systems provide an opportunity to improve the efficacy of a therapeutic agent whilst minimising side effects and also offer the advantage of favourable treatment regimens. The prostate‐specific membrane antigen (PSMA) targeting agents PSMA‐11 and PSMA‐617, which accumulate in prostate tumours, allows for [68Ga]Ga3+‐radiolabelling and PET imaging of PSMA‐expression in vivo. We herein report the formulation of [68Ga]Ga‐PSMA‐617 into a ME ≤40 nm including its evaluation for improved cellular toxicity and in vivo biodistribution. The [68Ga]Ga‐PSMA‐617‐ME was tested in vitro for its cytotoxicity to HEK293 and PC3 cells. [68Ga]Ga‐PSMA‐617‐ME was administered intravenously in BALB/c mice followed by microPET/CT imaging and ex vivo biodistribution determination. [68Ga]Ga‐PSMA‐617‐ME indicated negligible cellular toxicity at different concentrations. A statistically higher tolerance towards the [68Ga]Ga‐PSMA‐617‐ME occurred at 0.125mg/ml by HEK293 cells compared to PC3 cells. The biodistribution in wild‐type BALB/C mice showed the highest amounts of radioactivity (%ID/g) presented in the kidneys (31%) followed by the small intestine (10%) and stomach (9%); the lowest uptake was seen in the brain (0.5%). The incorporation of [68Ga]Ga‐PSMA‐617 into ME was successfully demonstrated and resulted in a stable non‐toxic formulation as evaluated by in vitro and in vivo means.
- 1 May 2018
- Published by Elsevier in Food Research International
- Vol. 107, 227-247
Impact of wall material physicochemical characteristics on the stability of encapsulated phytochemicals: A review
- 1 May 2018
- Published by Elsevier in Food Research International
- Vol. 107, 227-247
Impact of wall material physicochemical characteristics on the stability of encapsulated phytochemicals: A review
- 24 October 2017
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 43, 267-273
Synthesis, characterization and in vitro cytotoxicity evaluation of polyamidoamine conjugate containing pamidronate and platinum drug
- 24 October 2017
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 43, 267-273
Synthesis, characterization and in vitro cytotoxicity evaluation of polyamidoamine conjugate containing pamidronate and platinum drug
- 1 May 2017
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 102, 161-171
Supercritical antisolvent co-precipitation of rifampicin and ethyl cellulose
- 1 May 2017
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 102, 161-171
Supercritical antisolvent co-precipitation of rifampicin and ethyl cellulose
- 1 February 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 499 (1-2) , 205-216
Micronization, characterization and in-vitro dissolution of shellac from PGSS supercritical CO 2 technique
- 1 February 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 499 (1-2) , 205-216
Micronization, characterization and in-vitro dissolution of shellac from PGSS supercritical CO 2 technique
- 9 June 2015
- Published by Springer Nature in Pharmaceutical Research
- Vol. 32 (9) , 3119
Erratum to: Curdlan-conjugated PLGA Nanoparticles possess macrophage stimulant activity and drug delivery capabilities
- 9 June 2015
- Published by Springer Nature in Pharmaceutical Research
- Vol. 32 (9) , 3119
Erratum to: Curdlan-conjugated PLGA Nanoparticles possess macrophage stimulant activity and drug delivery capabilities
- 1 November 2014
- Published by Elsevier in The Journal of Supercritical Fluids
- Vol. 95, 106-117
Preparation of rifampicin/poly(d,l-lactice) nanoparticles for sustained release by supercritical assisted atomization technique
- 1 November 2014
- Published by Elsevier in The Journal of Supercritical Fluids
- Vol. 95, 106-117
Preparation of rifampicin/poly(d,l-lactice) nanoparticles for sustained release by supercritical assisted atomization technique
- 8 October 2013
- Published by Informa Healthcare in Expert Opinion on Drug Delivery
- Vol. 10 (12) , 1725-1734
State of the art and future directions in nanomedicine for tuberculosis
Tuberculosis (TB) ranks the second leading cause of death from an infectious disease worldwide. However, treatment of TB is affected by poor patient compliance due to the requirement for daily drug administration, for lengthy periods of time, often with severe drug-induced side effects. Nanomedicines have the potential to improve treatment outcomes by providing therapies with reduced drug doses, administered less frequently, under shortened treatment durations. In this article, we present the pathophysiology of the disease, focusing on pulmonary TB and the characteristics of drugs used in treatment and discuss the application of nanomedicines within this scope. We also discuss new formulation approaches for TB nanomedicines and directions for future research. Nanomedicines have the potential to improve TB treatment outcomes. New approaches such as nanoparticle systems able to impact the immune response of macrophages and deliver drug intracellularly, as well as the use of polymer-drug conjugates for drug delivery, are likely to play an important role in TB nanomedicines in future. However, further research is required before TB nanomedicines can be translated to the clinic.
- 8 October 2013
- Published by Informa Healthcare in Expert Opinion on Drug Delivery
- Vol. 10 (12) , 1725-1734
State of the art and future directions in nanomedicine for tuberculosis
Tuberculosis (TB) ranks the second leading cause of death from an infectious disease worldwide. However, treatment of TB is affected by poor patient compliance due to the requirement for daily drug administration, for lengthy periods of time, often with severe drug-induced side effects. Nanomedicines have the potential to improve treatment outcomes by providing therapies with reduced drug doses, administered less frequently, under shortened treatment durations. In this article, we present the pathophysiology of the disease, focusing on pulmonary TB and the characteristics of drugs used in treatment and discuss the application of nanomedicines within this scope. We also discuss new formulation approaches for TB nanomedicines and directions for future research. Nanomedicines have the potential to improve TB treatment outcomes. New approaches such as nanoparticle systems able to impact the immune response of macrophages and deliver drug intracellularly, as well as the use of polymer-drug conjugates for drug delivery, are likely to play an important role in TB nanomedicines in future. However, further research is required before TB nanomedicines can be translated to the clinic.